<DOC>
	<DOCNO>NCT02722954</DOCNO>
	<brief_summary>The purpose study test efficacy safety experimental drug , demcizumab , give combination pembrolizumab . Demcizumab humanize monoclonal antibody develop target cancer stem cell . Demcizumab may block growth cancer stem cell , remain cancer cell , may also impair productive growth new blood vessel , tumor need grow spread . This study sponsor OncoMed Pharmaceuticals , refer OncoMed Sponsor consent form .</brief_summary>
	<brief_title>A Phase 1b Study Demcizumab Plus Pembrolizumab Locally Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description>This open-label , Phase 1b dose escalation expansion study demcizumab plus pembrolizumab design evaluate safety , efficacy pharmacokinetics demcizumab combination pembrolizumab patient advance metastatic solid tumor . This study consist screen period , treatment period post-treatment follow period patient follow survival approximately 12 month . Patients enrol two stage : dose-escalation stage expansion phase . Approximately 42 patient enrol study approximately 10 study center United States ( U.S ) Europe .</detailed_description>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>1 . Measurable disease per response evaluation criterion solid tumor ( RECIST ) v1.1 2 . Availability formalinfixed paraffinembedded ( FFPE ) tumor tissue , either fresh coreneedlebiopsied archived 3 . Age &gt; 21 year 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 5 . Adequate organ marrow function 6 . For woman childbearing potential men partner childbearing potential , agreement ( patient and/or partner ) use two effective form contraception study entry least 6 month termination visit . 7 . Ability understand willingness sign write informed consent document 1 . Treatment anticancer therapy , include radiotherapy , chemotherapy , biologic therapy , herbal therapy within 3 week 5 halflives ( systemic agent ) whichever short 2 . Receiving investigational agent anticancer therapy 3 . Active infection require antibiotic 4 . Patients brain metastasis ( treat untreated ) leptomeningeal disease , uncontrolled seizure disorder , active neurologic disease 5 . History interstitial lung disease active , noninfectious pneumonitis require oral intravenous corticosteroid 6 . Prior radiation chest wall mediastinum radiation field involve heart 7 . Significant intercurrent illness limit patient 's ability participate study may result death next 18 month 8 . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior enrollment , anticipation need major surgical procedure course study 9 . Pregnant nursing woman 10 . New York Heart Association Classification II , III , IV 11 . Acute prior study treatment relate toxicity ( except alopecia ) resolve Grade &lt; = 1 unless deem stable investigator 12 . Inability comply study follow procedure</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>malignancy</keyword>
	<keyword>metastatic</keyword>
	<keyword>Demcizumab</keyword>
	<keyword>Pembrolizumab</keyword>
	<keyword>Phase 1b</keyword>
</DOC>